Study guide
6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization
Certified Burn Registered Nurse CBRN
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Foundations of Burn Care
1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones
2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response
2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology
3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria
3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics
4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)
4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy
5 Chapter 5: Airway Management & Inhalation Injury Management
5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)
6 Chapter 6: Acute Multisystem Assessment & Critical Care Management
6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection
7 Chapter 7: Hypermetabolism & Nutritional Support
7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation
8 Chapter 8: Pain Management in Burn Care
8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction
9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus
9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients
10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings
10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances
11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure
11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management
12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy
12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion
13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries
13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy
14 Chapter 14: Special Burn Populations & Cutaneous Syndromes
14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries
15 Chapter 15: Rehabilitation, Scar Management & Reconstruction
15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management
16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage
16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response
6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization
Key Takeaways Explain This Topic AI
The cardiovascular response to severe burn trauma (≥20% TBSA) is biphasic: an initial hypodynamic Ebb/Resuscitation Phase (0–48 hours) marked by severe reduction in cardiac output (often 30–50% drop) and high systemic vascular resistance (SVR), followed by a prolonged hyperdynamic Flow Phase (>48–72 hours) with cardiac output reaching 1.5 to 2.5 times baseline.
Early post-burn myocardial depression occurs immediately following thermal injury and precedes significant plasma volume loss; it is mediated by circulating myocardial depressant factors (TNF-alpha, IL-1beta, IL-6, reactive oxygen species) and impaired sarcoplasmic reticulum intracellular calcium handling.
Continuous arterial line catheterization is mandatory in extensive burns for beat-to-beat systemic blood pressure monitoring, arterial blood gas sampling, and dynamic pulse pressure / stroke volume variation analysis, as non-invasive cuff measurements are notoriously inaccurate due to progressive interstitial extremity edema.
Advanced hemodynamic monitoring modalities (such as transpulmonary thermodilution [PiCCO], pulse contour analysis [FloTrac/EV1000], and point-of-care echocardiography) provide functional preload indices (Stroke Volume Variation [SVV] and Pulse Pressure Variation [PPV]) that superiorly guide fluid titration compared to static central venous pressure (CVP) values.
Intravascular fluid resuscitation remains the primary foundational therapy for burn shock; vasopressors (e.g., norepinephrine, vasopressin) are indicated only for refractory distributive vasodilation after intravascular volume has been restored. Pure alpha-1 adrenergic agonists (phenylephrine) and high-dose epinephrine must be avoided due to profound splanchnic and dermal microvascular vasoconstriction that accelerates tissue necrosis in Jackson's zone of stasis.
Last updated: August 2026
6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization
Core Knowledge: Major thermal trauma involving ≥ 20 % \ge 20\% ≥ 20% Total Body Surface Area (TBSA) precipitates profound, life-threatening cardiovascular instability. Unlike standard hypovolemic shock, burn shock represents a complex hybrid of hypovolemic, distributive, and cardiogenic shock mechanisms. Understanding the transition from the initial hypodynamic ebb phase to the persistent hyperdynamic flow phase , recognizing intrinsic myocardial depression, and deploying advanced hemodynamic monitoring are critical competencies for the Certified Burn Registered Nurse (CBRN).
1. The Biphasic Cardiovascular Paradigm in Severe Burns
Thermal trauma induces an immediate, systemic neuroendocrine, inflammatory, and microvascular storm that divides the patient's cardiovascular course into two distinct physiological phases: the Ebb (Resuscitation) Phase and the Flow (Hypermetabolic) Phase . BIPHASIC CARDIOVASCULAR TRAJECTORY IN SEVERE BURNS
- ┌────────────────────────────────────────┬────────────────────────────────────────┐
- │ EBB / RESUSCITATION PHASE │ FLOW / HYPERMETABOLIC PHASE │
- │ (0 – 48 Hours) │ (>48 – 72 Hours) │
- ├────────────────────────────────────────┼────────────────────────────────────────┤
- │ • Cardiac Output: Markedly decreased │ • Cardiac Output: Markedly elevated │
- │ (30–50% drop below baseline) │ (1.5–2.5x normal baseline; 10-18 L/m)│
- │ • SVR: Markedly elevated (vasospasm) │ • SVR: Low to normal (vasodilation) │
- │ • Heart Rate: Moderate tachycardia │ • Heart Rate: Severe tachycardia │
- │ • Stroke Volume: Severely reduced │ • Stroke Volume: Normal to supranormal │
- │ • Intravascular Volume: Severe deficit │ • Intravascular Volume: Stabilizing │
- │ • Oxygen Delivery (DO2): Depressed │ • Oxygen Delivery (DO2): Supranormal │
- │ • Splanchnic Flow: Severely restricted │ • Splanchnic Flow: Hyperemic │
- └────────────────────────────────────────┴────────────────────────────────────────┘
- The Hypodynamic Ebb Phase (0 to 48 Hours)
During the initial 24 to 48 hours post-injury, the cardiovascular system is characterized by severe hypoperfusion and cellular energy deprivation:
Cardiac Output (CO): Plummets by 30% to 50% within minutes of injury , reaching nadirs well before substantial intravascular fluid volume has been lost to the interstitial spaces.
Systemic Vascular Resistance (SVR): Spikes dramatically. The massive release of endogenous catecholamines (epinephrine and norepinephrine), vasopressin, angiotensin II, and thromboxane A 2 A_2 A 2 causes intense peripheral and splanchnic vasoconstriction in an effort to maintain central mean arterial pressure (MAP).
Hemoconcentration: Extensive plasma extravasation through hyperpermeable capillary beds increases blood viscosity and hematocrit (often 50% to 65%), creating microvascular sludging and elevating myocardial afterload.
The Hyperdynamic Flow Phase (>48 to 72 Hours to Months)
As capillary integrity is restored and interstitial third-space fluid begins to resorb into the intravascular compartment, the body transitions into the hypermetabolic flow phase:
Supranormal Cardiac Output: Cardiac output surges to 150% to 250% of normal baseline (frequently 10 to 18 L/min; cardiac index 4.5 to 7.0 L/min/m²). This state can persist for 12 to 24 months post-injury.
Systemic Vascular Resistance: Decreases significantly due to peripheral vasodilation driven by sustained inflammatory mediators, elevated core body temperature setpoints (~38.5°C), and profound tissue metabolic demand.
Wide Pulse Pressures & Tachycardia: Baseline resting heart rates commonly exceed 110 to 130 beats/min in adults, accompanied by bounding peripheral pulses and wide pulse pressures.
2. Pathophysiology of Early Burn Myocardial Depression
A hallmark of burn shock that distinguishes it from pure hemorrhagic shock is early intrinsic myocardial depression . Experimental and clinical studies demonstrate that left and right ventricular contractility drops precipitously within 1 to 2 hours of thermal injury, even when left ventricular end-diastolic volume (preload) is artificially maintained with rapid volume infusions. MECHANISMS OF BURN MYOCARDIAL DEPRESSION
- ┌────────────────────────────────────────────────────────────────────────────────────────┐
- │ Circulating Myocardial Depressant Factors (MDF): TNF-α, IL-1β, IL-6, Endothelin-1 │
- │ │ │
- │ ▼ │
- │ Disrupted Sarcoplasmic Reticulum Ryanodine Receptors & Downregulated SERCA2a Pumps │
- │ │ │
- │ ▼ │
- │ Impaired Intracellular Calcium Cycling & Sarcoplasmic Ca2+ Influx During Systole │
- │ │ │
- │ ▼ │
- │ Excessive Catecholamine Surge ──► Beta-Adrenergic Receptor Uncoupling & Desensitization│
- │ │ │
- │ ▼ │
- │ Myocardial Oxidative Stress, Lipid Peroxidation & Depressed Myofibrillar ATP Delivery │
- │ │ │
- │ ▼ │
- │ PRECIPITOUS DROP IN LEFT VENTRICULAR STROKE WORK INDEX (LVSWI) & EF │
- └────────────────────────────────────────────────────────────────────────────────────────┘
Key Molecular Mechanisms:
Myocardial Depressant Cytokines: Pro-inflammatory cytokines—primarily Tumor Necrosis Factor-alpha (TNF-α) , Interleukin-1beta (IL-1β) , and Interleukin-6 (IL-6) —exert direct negative inotropic effects on cardiac myocytes. They induce inducible nitric oxide synthase (iNOS), producing excess nitric oxide and peroxynitrite that depress myofibrillar responsiveness to calcium.
Disrupted Calcium Homeostasis: Thermal trauma causes severe dysregulation of the sarcoplasmic reticulum calcium ATPase (SERCA2a) and ryanodine receptors. Intracellular calcium transient amplitude is diminished during systole, resulting in impaired cross-bridge cycling and reduced force generation.
Beta-Adrenergic Desensitization: Massive systemic levels of circulating epinephrine and norepinephrine saturate and uncouple myocardial beta-1 adrenergic receptors via G-protein receptor kinase (GRK) phosphorylation, rendering the myocardium relatively refractory to endogenous adrenergic stimulation.
Oxidative Myocardial Injury: Free radicals generated by xanthine oxidase and activated neutrophils induce lipid peroxidation of myocardial cell membranes and mitochondrial dysfunction, lowering cellular ATP generation.
3. Hemodynamic Monitoring Modalities in the Burn ICU
Accurate assessment of volume status, ventricular performance, and tissue perfusion is essential to navigate the narrow therapeutic corridor between under-resuscitation (leading to hypoperfusion, acute tubular necrosis, and burn conversion) and over-resuscitation (leading to fluid creep, pulmonary edema, and abdominal compartment syndrome).
Monitoring Modality Clinical Utility in Burns Limitations & Technical Considerations
Invasive Arterial Line Beat-to-beat blood pressure; serial arterial blood gases (ABG), lactate, and base deficit; continuous pulse contour waveform analysis. Mandatory in burns ≥ 20 % \ge 20\% ≥ 20% TBSA. Non-invasive cuff pressures significantly overestimate true intra-arterial pressure in the presence of severe edema.
Central Venous Catheter (CVC) Central venous pressure (CVP) trends; central venous oxygen saturation ( S c v O 2 ScvO_2 S c v O 2 ); central vasoactive drug infusion. Static CVP values (mmHg) correlate poorly with true preload and fluid responsiveness. Useful primarily for continuous S c v O 2 ScvO_2 S c v O 2 monitoring (target ≥ 70 % \ge 70\% ≥ 70% ).
Transpulmonary Thermodilution (PiCCO / EV1000) Measures Extravascular Lung Water Index (EVLWI), Global End-Diastolic Volume Index (GEDVI), and continuous Cardiac Index (CI). Highly valuable in massive burns and inhalation injury. EVLWI directly quantifies pulmonary capillary leak and impending ARDS.
Pulse Contour Analysis (FloTrac / Vigileo) Real-time Stroke Volume (SV), Cardiac Output (CO), and dynamic fluid responsiveness indices (SVV / PPV). Requires an arterial line. Accurate only in patients in sinus rhythm who are fully mechanically ventilated with fixed tidal volumes ( ≥ 8 mL/kg \ge 8\text{ mL/kg} ≥ 8 mL/kg ).
Point-of-Care Echocardiography (TTE / TEE) Visualizes biventricular systolic function, chamber dimensions, inferior vena cava (IVC) collapsibility/distensibility, and pericardial effusion. Operator-dependent; chest wall dressings, thoracic eschar, and subcutaneous emphysema can compromise transthoracic acoustic windows.
4. Static vs. Dynamic Indices of Fluid Responsiveness
Traditional static markers of volume (e.g., CVP, Pulmonary Capillary Wedge Pressure [PCWP]) have proven notoriously unreliable in critical burn care because altered chest wall compliance (circumferential torso eschar), positive-pressure mechanical ventilation, and myocardial stiffness distort pressure-volume relationships. DYNAMIC INDICES FOR FLUID RESPONSIVENESS IN THE BURN ICU
- ┌────────────────────────────────────────────────────────────────────────────────────────┐
- │ Stroke Volume Variation (SVV) / Pulse Pressure Variation (PPV): │
- │ │
- │ SVV = (SV_max - SV_min) / [(SV_max + SV_min) / 2] x 100% │
- │ │
- │ • SVV / PPV > 12–13%: Patient is on the steep portion of the Frank-Starling curve; │
- │ highly likely to increase stroke volume and cardiac output in response to fluid. │
- │ • SVV / PPV < 10%: Patient is on the flat plateau of the Frank-Starling curve; │
- │ additional crystalloids will NOT augment cardiac output, but WILL worsen edema. │
- │ │
- │ PREREQUISITES FOR ACCURATE DYNAMIC MONITORING: │
- │ [1] Controlled mechanical ventilation with no spontaneous breathing efforts │
- │ [2] Tidal volume ≥ 8 mL/kg of predicted body weight (PBW) │
- │ [3] Absence of cardiac dysrhythmias (atrial fibrillation, frequent PVCs) │
- │ [4] Closed chest cavity (no open thoracic trauma or massive pneumothorax) │
- └────────────────────────────────────────────────────────────────────────────────────────┘
- 5. Vasoactive and Inotropic Pharmacotherapy Principles
In acute burn shock, fluid resuscitation is the primary intervention . Vasopressors must never be used as a substitute for adequate intravascular crystalloid volume repletion.
[!CRITICAL]
Administering vasopressors to an unresuscitated, hypovolemic burn patient produces catastrophic peripheral and splanchnic microvascular collapse. Intense alpha-1 vasoconstriction turns viable, stasis-injured dermis into full-thickness necrotic tissue (burn depth conversion) and precipitates ischemic gut necrosis. VASOPRESSOR & INOTROPE ALGORITHM
- ┌──────────────────────────────────────────────────────────────────────────────────────┐
- │ Hypotension / Hypoperfusion (MAP < 65 mmHg, Lactate > 2) │
- └──────────────────────────────────────────┬───────────────────────────────────────────┘
- │
- ▼
- ┌──────────────────────────────────────────────────────────────────────────────────────┐
- │ FIRST: Optimize Intravascular Preload (Titrate LR, SVV > 12%, ScvO2) │
- └──────────────────────────────────────────┬───────────────────────────────────────────┘
- │
- ┌──────────────────────────┴──────────────────────────┐
- ▼ ▼
- ┌────────────────────────┐ ┌────────────────────────┐
- │ Persistent Vasodilation│ │ Depressed Myocardial │
- │ (Low SVR, Normal SVV) │ │ Contractility / ScvO2 │
- └────────────┬───────────┘ └───────────┬────────────┘
- │ │
- ▼ ▼
- ┌────────────────────────┐ ┌────────────────────────┐
- │ 1st Line: NOREPINEPHRINE│ │ 1st Line: DOBUTAMINE │
- │ (Potent α1 + moderate │ │ (β1 inotrope: augments │
- │ β1 inotrope support) │ │ stroke volume & DO2) │
- │ │ │ │
- │ 2nd Line: VASOPRESSIN │ │ 2nd Line: MILRINONE │
- │ (0.03–0.04 units/min; │ │ (Inodilator: PDE-3 │
- │ restores V1 tone) │ │ inhibitor; caution │
- │ │ │ with hypotension) │
- │ STRICTLY AVOID: │ └────────────────────────┘
- │ • Phenylephrine (pure │
- │ α1 micro-ischemia) │
- │ • High-dose Epinephrine│
- │ (lactic acidosis) │
- └────────────────────────┘
- 1. Norepinephrine (First-Line Vasopressor)
Receptor Target: Strong alpha-1 adrenergic vasoconstriction with moderate beta-1 inotropic and chronotropic activity.
Indication: Refractory hypotension (MAP < 65 mmHg <65\text{ mmHg} < 65 mmHg ) caused by early distributive SIRS or late septic vasodilation, occurring after dynamic preload indicators confirm adequate volume resuscitation.
Clinical Benefit: Restores perfusion pressure to vital organs without inducing the extreme tachyarrhythmias and hyperlactatemia seen with epinephrine infusions.
2. Vasopressin (Second-Line / Adjunctive Vasopressor)
Receptor Target: Direct vascular V 1 V_1 V 1 receptor agonist.
Indication: Refractory vasodilatory shock as an adjunct to norepinephrine at a fixed rate of 0.03 to 0.04 units/min .
Clinical Benefit: Circumvents adrenergic receptor down-regulation and blunts excessive sympathetic vasoconstriction in the pulmonary vascular bed.
3. Dobutamine (First-Line Inotrope)
Receptor Target: Potent beta-1 agonist with mild beta-2 and alpha-1 activity.
Indication: Persistent tissue hypoperfusion (low S c v O 2 < 70 % ScvO_2 < 70\% S c v O 2 < 70% , elevated lactate) accompanied by echocardiographic evidence of depressed left ventricular contractility despite optimized intravascular volume and normalized MAP.
Dosing: Initiated at 2.5 to 10 mcg/kg/min .
4. Agents to Strictly Avoid in Acute Burn Resuscitation
Phenylephrine: Pure alpha-1 agonist with zero inotropic activity. Causes intense cutaneous and mesenteric arteriolar constriction, converting partial-thickness burns into non-viable full-thickness wounds in Jackson's zone of stasis and starving the gastrointestinal mucosa.
High-Dose Epinephrine: Induces severe tachycardia, escalates myocardial oxygen consumption ( M V O 2 MVO_2 M V O 2 ), triggers splanchnic vasoconstriction, and stimulates excessive skeletal muscle aerobic glycolysis via beta-2 receptors, resulting in confusing, non-hypoxic lactic acidosis.